Clinical efficacy of Wendanningxin granule in the treatment of mild to moderate anxiety
- Conditions
- moderate anxiety
- Registration Number
- ITMCTR2022000012
- Lead Sponsor
- Guang'anmen Hospital, Chian Academy of Chinese Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Age: 18 ~ 65 years old, both male and female;
(2) Conform to the diagnostic criteria of anxiety disorder in western medicine and the diagnostic criteria of heart and gall Qi deficiency syndrome;
(3) At the time of enrollment, the total score of HAMA Anxiety Scale (17 items) was = 14 and = 29;
(4) The total score of HAMD depression scale = 7 at the time of enrollment;
(5) Informed consent and sign the informed consent form.
(1) Those with suicidal tendencies;
(2) Severe anxiety (HAMA total score >29);
(3) Anxiety attack secondary to other mental or physical diseases and accompanied by severe psychotic symptoms;
(4) Patients with severe diseases of other systems and severe heart, liver and kidney dysfunction (including ALT and AST 1.5 times higher than normal);
(5) Those who had taken anti anxiety agents within four weeks before enrollment;
(6) Pregnancy or lactation or pregnancy; Women of childbearing age with positive urine pregnancy test;
(7) Known alcoholics or drug addicts.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hamilton Anxiety Scale;Self rating Anxiety Scale;Near infrared quantitative brain function imaging;
- Secondary Outcome Measures
Name Time Method Hamilton Depression Scale;Pittsburgh sleep quality index;